BACKGROUND A significant subset of individuals with epilepsy fails to respond to currently available antiepileptic drugs,resulting in heightened mortality rates,psychosocial challenges,and a diminished quality of life...BACKGROUND A significant subset of individuals with epilepsy fails to respond to currently available antiepileptic drugs,resulting in heightened mortality rates,psychosocial challenges,and a diminished quality of life.Genetic factors,particularly within the SCN1A gene,and the pro-inflammatory cytokine response is important in intricating the drug resistance in idiopathic epilepsy cases.In this extended study,we determined the correlation of rs6732655A/T single nucleotide polymorphism to understand the causative association of SCN1A gene with epilepsy drug resistance and inflammatory response.AIM To find the correlation of SCN1A gene rs6732655A/T polymorphism with the drug-resistant epilepsy and inflammatory response.METHODS The study enrolled 100 age and sex-matched patients of both drug-resistant and drug-responsive epilepsy cases.We analysed the rs6732655A/T polymorphism to study its association and causative role in drug-resistant epilepsy cases using restriction fragment length polymorphism technique.The diagnostic performance of interleukin(IL)-1β,IL-6,and high mobility group box 1(HMGB1)protein levels was evaluated in conjunction with genotypic outcome receiver operating characteristic analysis.RESULTS AT and AA genotypes of rs6732655 SCN1A gene polymorphism were associated with higher risk of drug resistance epilepsy.Serum biomarkers IL-6,IL1βand HMGB1 demonstrated diagnostic potential,with cutoff values of 4.63 pg/mL,59.52 pg/mL and 7.99 ng/mL,respectively,offering valuable tools for epilepsy management.Moreover,specific genotypes(AA and AT)were found to be linked to the elevated levels of IL-1βand IL-6 and potentially reflecting increased oxidative stress and neuro-inflammation in drug-resistant cases supporting the previous reported outcome of high inflammatory markers response in drug resistance epilepsy.CONCLUSION SCN1A genotypes AA and AT are linked to higher drug-resistant epilepsy risk.These findings underscore the potential influence of inflammation and genetics on epilepsy treatment resistance.展开更多
目的:分析SCN1A、SCN2A基因多态性对丙戊酸钠治疗癫痫患儿的疗效影响。方法:采用PCR和Sanger测序法检测128例丙戊酸钠规范治疗的癫痫患儿(有效组76例、无效组52例)外周血SCN1A(rs10188577、rs2298771、rs3812718、rs1813502)、SCN2A(rs2...目的:分析SCN1A、SCN2A基因多态性对丙戊酸钠治疗癫痫患儿的疗效影响。方法:采用PCR和Sanger测序法检测128例丙戊酸钠规范治疗的癫痫患儿(有效组76例、无效组52例)外周血SCN1A(rs10188577、rs2298771、rs3812718、rs1813502)、SCN2A(rs2304016、rs17183814)多态性。采用非条件Logistic回归分析基因型、等位基因频率与丙戊酸钠疗效的关系,分析不同基因型患者丙戊酸钠血药浓度的差异。结果:SCN1A基因rs3812718位点多态性与丙戊酸钠治疗效果有关。携带GA和AA基因型的患者采用丙戊酸钠治疗有效(GG vs GA:OR=1.186,95%CI 0.965~2.304,P=0.015;GG vs AA:OR=1.252,95%CI 1.007~3.254,P=0.002)。有效组SCN1A基因rs3812718位点A等位基因频率明显高于无效组(OR=1.452,95%CI 1.052~2.695,P=0.010)。其余基因位点组间比较差异均无统计学意义(P>0.05)。结论:SCN1A基因rs3812718位点多态性可能与丙戊酸钠抗癫痫效应有关。展开更多
文摘BACKGROUND A significant subset of individuals with epilepsy fails to respond to currently available antiepileptic drugs,resulting in heightened mortality rates,psychosocial challenges,and a diminished quality of life.Genetic factors,particularly within the SCN1A gene,and the pro-inflammatory cytokine response is important in intricating the drug resistance in idiopathic epilepsy cases.In this extended study,we determined the correlation of rs6732655A/T single nucleotide polymorphism to understand the causative association of SCN1A gene with epilepsy drug resistance and inflammatory response.AIM To find the correlation of SCN1A gene rs6732655A/T polymorphism with the drug-resistant epilepsy and inflammatory response.METHODS The study enrolled 100 age and sex-matched patients of both drug-resistant and drug-responsive epilepsy cases.We analysed the rs6732655A/T polymorphism to study its association and causative role in drug-resistant epilepsy cases using restriction fragment length polymorphism technique.The diagnostic performance of interleukin(IL)-1β,IL-6,and high mobility group box 1(HMGB1)protein levels was evaluated in conjunction with genotypic outcome receiver operating characteristic analysis.RESULTS AT and AA genotypes of rs6732655 SCN1A gene polymorphism were associated with higher risk of drug resistance epilepsy.Serum biomarkers IL-6,IL1βand HMGB1 demonstrated diagnostic potential,with cutoff values of 4.63 pg/mL,59.52 pg/mL and 7.99 ng/mL,respectively,offering valuable tools for epilepsy management.Moreover,specific genotypes(AA and AT)were found to be linked to the elevated levels of IL-1βand IL-6 and potentially reflecting increased oxidative stress and neuro-inflammation in drug-resistant cases supporting the previous reported outcome of high inflammatory markers response in drug resistance epilepsy.CONCLUSION SCN1A genotypes AA and AT are linked to higher drug-resistant epilepsy risk.These findings underscore the potential influence of inflammation and genetics on epilepsy treatment resistance.
文摘目的:分析SCN1A、SCN2A基因多态性对丙戊酸钠治疗癫痫患儿的疗效影响。方法:采用PCR和Sanger测序法检测128例丙戊酸钠规范治疗的癫痫患儿(有效组76例、无效组52例)外周血SCN1A(rs10188577、rs2298771、rs3812718、rs1813502)、SCN2A(rs2304016、rs17183814)多态性。采用非条件Logistic回归分析基因型、等位基因频率与丙戊酸钠疗效的关系,分析不同基因型患者丙戊酸钠血药浓度的差异。结果:SCN1A基因rs3812718位点多态性与丙戊酸钠治疗效果有关。携带GA和AA基因型的患者采用丙戊酸钠治疗有效(GG vs GA:OR=1.186,95%CI 0.965~2.304,P=0.015;GG vs AA:OR=1.252,95%CI 1.007~3.254,P=0.002)。有效组SCN1A基因rs3812718位点A等位基因频率明显高于无效组(OR=1.452,95%CI 1.052~2.695,P=0.010)。其余基因位点组间比较差异均无统计学意义(P>0.05)。结论:SCN1A基因rs3812718位点多态性可能与丙戊酸钠抗癫痫效应有关。
